clinical trial · NCT04381689
Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants
Il-Yang Pharm. Co., Ltd.·phase3·active not recruiting·n = 245
HealthyIL-YANG FLU Vaccine Prefilled Syringe INJ.Fluarix Tetra Pre-filled Syringe
brief summary
The purpose of this study is to evaluate the safety and immunogenicity of IL-YANG Inactivated Split Influenza Vaccine (IL-YANG Quadrivalent Seasonal Influenza Vaccine) in healthy infants from 6 months to under 3 years of age(≥ 6 months and \< 3 years)
started
Oct 23, 2024
primary completion
May 20, 2025
completion
May 31, 2026
last updated
Mar 25, 2026
detailed description
The study is an Randomized, Double-blind, Active controlled Phase III study.
official title
Phase Ⅲ, Randomized, Double-blind, Active Controlled to Evaluate the Immunogenicity and Safety of "IL-YANG Quadrivalent Seasonal Influenza Vaccine" in Healthy Infants From 6 Months to Under 3 Years of Age(≥ 6 Months and < 3 Years)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol